Displaying drugs 7901 - 7925 of 8039 in total
Acetylcysteine zidrimer
Investigational
TBC-3711
TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Investigational
Abafungin
Investigational
Siplizumab
Investigational
Onercept
Investigational
alpha-Conotoxin VC 1.1
Investigational
G4460
Investigational
Vasomera
Investigational
SNS-032
Investigational
Sufugolix
Investigational
Zenarestat
Experimental
Epothilone D
Investigational
Annamycin
Investigational
FT516
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
Darapladib
Investigational
Refametinib
Investigational
RG-7795
Investigational
Vitespen
Investigational
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
PRX-07034
Investigational
Alicaforsen
Investigational
AEOL-10150
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Investigational
Labetuzumab
Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.
Investigational
Displaying drugs 7901 - 7925 of 8039 in total